Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Prolonged viral shedding may pose a threat to the control of coronavirus disease 2019 (COVID‐19), and data on the duration of SARS‐CoV‐2 shedding are still limited, with the associated factors being unknown.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>All adult patients with laboratory‐confirmed COVID‐19 were included in this retrospective cross‐sectional study in two designated hospitals during 21 January 2020‐16 March 2020 in Anhui, China. In all patients, data on the duration of SARS‐CoV‐2 RNA shedding were analyzed by reviewing all RNA detection results during hospitalization. Additionally, demographic, clinical, treatment, laboratory and outcome data were also collected from electronic medical records. Factors associated with prolonged viral shedding were analyzed with the Cox proportional hazards model.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Among 181 patients, the mean age was 44.3±13.2 years, and 55.2% were male. The median duration of viral shedding from illness onset was 18.0 days (IQR 15.0‐24.0). Prolonged viral shedding was associated with longer hospital stays (P<0.001) and higher medical costs (P<0.001). The severity of COVID‐19 had nothing to do with prolonged shedding. Moreover, the median time from onset to antiviral treatment initiation was 5.0 days (IQR 3.0‐7.0). Delayed antiviral treatment (HR 0.976 [95% CI, 0.962‐0.990]) and lopinavir/ritonavir + IFN‐α combination therapy as the initial antiviral treatment (HR 1.649 [95% CI, 1.162‐2.339]) were independent factors associated with prolonged SARS‐CoV‐2 RNA shedding.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>SARS‐CoV‐2 showed prolonged viral shedding, causing increased hospital stays and medical costs. Early initiation of lopinavir/ritonavir + IFN‐α combination therapy may help shorten the duration of SARS‐CoV‐2 shedding.</p><p>This article is protected by copyright. All rights reserved.</p></section>

Duration of SARS‐CoV‐2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID‐19

Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)

Clinical Characteristics and Factors Associated with Long-Term Viral Excretion in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study

Clinical Features in Coronavirus Disease 2019 (COVID-19) Patients with Early Clearance and Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) RNA.

Prevalence and Persistent Shedding of Fecal SARS-CoV-2 RNA in Patients with COVID-19 Infection: A Systematic Review and Meta-analysis.

Factors associated with delayed viral shedding in COVID-19 infected patients: A retrospective small-scale study

Clinical Course and Factors Associated with Viral RNA Shedding and Radiologic Resolution in Patients with COVID-19: a Retrospective Study

Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease

Impact of Age on Duration of Viral RNA Shedding in Patients with COVID-19.

Prolonged viral RNA shedding is associated with improved prognosis in COVID-19 patients: a retrospective cohort study

Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study

Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID‐19: A retrospective study in two designated hospitals in Anhui, China

Longitudinal Virological Changes and Underlying Pathogenesis in Hospitalized COVID-19 Patients in Guangzhou, China

Delayed Clearance of Viral RNA in Sputum for Severity COVID-19 Patients with Initial High Viral Load

Corticosteroid, Oseltamivir and Delayed Admission Are Independent Risk Factors for Prolonged Viral Shedding in Patients with Coronavirus Disease 2019.

Associations of Clinical Features and Dynamic Immune Response with the Duration of Viral RNA Shedding in Patients with COVID-19

Clinical predictors and RT-PCR profile of prolonged viral shedding in patients with SARS-CoV-2 Omicron variant in Shanghai: A retrospective observational study

Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients with COVID-19

Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis.

Characteristics of COVID-19 Patients With SARS-CoV-2 Positivity in Feces

Enhanced inflammation and suppressed adaptive immunity in COVID-19 with prolonged RNA shedding